Dermira Inc (DERM) : Aisling Capital reduced its stake in Dermira Inc by 89.43% during the most recent quarter end. The investment management company now holds a total of 102,593 shares of Dermira Inc which is valued at $3,230,654 after selling 868,230 shares in Dermira Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Dermira Inc makes up approximately 0.69% of Aisling Capital’s portfolio.
Other Hedge Funds, Including , Sphera Funds Management Ltd. reduced its stake in DERM by selling 50,000 shares or 41.67% in the most recent quarter. The Hedge Fund company now holds 70,000 shares of DERM which is valued at $2,204,300. Dermira Inc makes up approx 0.51% of Sphera Funds Management Ltd.’s portfolio. Tower Research Capital (trc) sold out all of its stake in DERM during the most recent quarter. The investment firm sold 1,678 shares of DERM which is valued $52,840.Blackrock Group Ltd boosted its stake in DERM in the latest quarter, The investment management firm added 21,534 additional shares and now holds a total of 218,774 shares of Dermira Inc which is valued at $6,889,193. Cable Hill Partners added DERM to its portfolio by purchasing 261 company shares during the most recent quarter which is valued at $8,420. Dermira Inc makes up approx 0.01% of Cable Hill Partners’s portfolio.
Dermira Inc closed down -0.19 points or -0.60% at $31.32 with 1,11,591 shares getting traded on Monday. Post opening the session at $31.62, the shares hit an intraday low of $30.94 and an intraday high of $31.71 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on Jun 2, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.